US cancels more $700 million funding for Moderna bird flu vaccine

The U.S. government has cancelled over $700 million in funding previously awarded to Moderna for late-stage development and purchase of its bird flu vaccine. This includes a $590 million award from January and an earlier $176 million grant. Moderna intends to seek alternative funding while also reporting positive interim data from a mid-stage trial assessing the vaccine's safety and immunogenicity.

Analysis

Moderna, Inc. (MRNA.O) has reported the cancellation of a U.S. contract concerning its bird flu vaccine program, a decision the article attributes to 'the Trump administration,' impacting over $700 million in funding designated for late-stage development and the government's right to purchase vaccine doses. This significant financial retraction encompasses $590 million awarded by the Biden administration in January and an additional $176 million granted by the U.S. Department of Health and Human Services last year. The termination of these substantial funds introduces considerable uncertainty regarding the advanced clinical progression and future U.S. government procurement of Moderna's H5N1 avian influenza vaccine candidate. In response to this setback, Moderna has stated its intention to explore alternative pathways for the vaccine's late-stage development and manufacturing. Simultaneously, the company announced positive interim data from a mid-stage clinical trial, which indicated favorable safety and immunogenicity for its H5 avian influenza vaccine candidate, though this scientific progress is now overshadowed by the immediate funding challenge for this specific program.

Key Decisions for Investors

• Investors should critically assess the future revenue potential and development timeline for Moderna's bird flu vaccine, given the cancellation of over $700 million in U.S. government funding creates a significant financial hurdle.
• Monitor Moderna's ability to secure alternative funding sources or strategic partnerships to advance its H5N1 vaccine candidate through late-stage trials and into manufacturing, as this will be crucial for realizing its value despite positive mid-stage trial data.
• Evaluate the potential impact of this contract cancellation on Moderna's broader relationship with government agencies for pandemic preparedness programs and consider if this signals increased risk for similar pipeline projects reliant on public funding.